Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea

NCT01130272 is registered in ClinicalTrials.gov with Furiex Pharmaceuticals, Inc as lead sponsor.

NCT NCT01130272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01130272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea
Lead sponsor
Furiex Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2010
Completion date
July 14, 2011
Enrollment
807 (actual)
Sites
288

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome